In vivo activity of humanized monoclonal anti-EGFR antibody EMD 72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude m…

Introduction: Deregulation of epidermal growth factor receptor (EGFR) pathways contributes to the progression of a wide range of cancers, and the EGFR is an attractive therapeutic target. The humanized EGFR-specific monoclonal antibody EMD 72000 has shown potent inhibitory activity in preclinical experiments and is under investigation in clinical studies. Material and Methods: Using the human L3.6pl pancreatic cancer cell line, we investigated whether the efficacy of EMD72000 can be enhanced in combination with gemcitabine. Nude mice were orthotopically injected with L3.6pl cells followed by biweekly treatment o…